Skip to main content
Cachet Pharmaceutical Co., Ltd. logo

Cachet Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002462 ISIN · CNE100000SN0 LEI · 300300CBONJS7HUOCX64 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,441 across all filing types
Latest filing 2014-03-27 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002462

About Cachet Pharmaceutical Co., Ltd.

https://www.cachet.com.cn

Cachet Pharmaceutical Co., Ltd. specializes in the distribution and retail of pharmaceutical products and medical devices. The company operates an extensive wholesale network and a chain of retail pharmacies, providing comprehensive supply chain solutions to healthcare institutions and end-consumers. Its core operations include the procurement, storage, and logistics of western medicines, traditional Chinese medicines, and high-value medical consumables. Cachet Pharmaceutical emphasizes modern logistics management and professional pharmaceutical services, leveraging a robust distribution infrastructure to ensure the efficient delivery of healthcare products. The company also focuses on hospital supply chain integration and community-based retail services to enhance healthcare accessibility.

Recent filings

Filing Released Lang Actions
独立董事关于第四届董事会第十二次会议相关事项的专项说明及独立意见
Audit Report / Information Classification · 95% confidence The document is an independent directors' special statement and opinion related to the 12th meeting of the 4th board of directors of 嘉事堂药业股份有限公司. It covers various topics such as the use of raised funds in 2013, internal control self-evaluation, senior management remuneration, related party transactions, securities investment, profit distribution proposal, and the reappointment of the audit firm for 2014. The document is a formal opinion letter by independent directors rather than a full audit report or annual report. It does not contain full financial statements or detailed financial data but provides independent opinions on specific governance and compliance matters. This type of document aligns best with Audit Report / Information (AR), which includes standalone audit-related reports and opinions by independent directors on internal controls and compliance, excluding full annual reports. FY 2013
2014-03-27 Chinese
关于募集资金年度存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the annual status of raised funds, including amounts raised, usage, project investment details, changes in investment projects, and compliance with regulatory requirements. It references approvals by the China Securities Regulatory Commission and Shenzhen Stock Exchange rules, and includes financial figures and audit confirmations related to the use of raised capital. The document is titled as a "专项报告" (special report) on the annual deposit and use of raised funds, which aligns with disclosures related to capital raising and fund usage. It is not an annual report, earnings release, or management discussion, but a specific report on capital raising and fund usage. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length and detail confirm it is a full report, not just an announcement or certification.
2014-03-27 Chinese
第四届董事会第十二次会议决议的公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 12th meeting of the 4th Board of Directors of 嘉事堂药业股份有限公司, held on March 26, 2014. It includes approvals of various reports such as the 2013 Board Work Report, 2013 Financial Statements, Profit Distribution Plan, Internal Control Reports, Social Responsibility Report, and plans for the 2013 Annual General Meeting. The document contains voting results and references to detailed reports published elsewhere (on the cninfo website). The document is not the full annual report itself but a formal announcement of board meeting decisions and approvals related to the annual report and other matters requiring shareholder approval. It is a typical Board/Management Information announcement about board meeting resolutions and related corporate governance matters. The document length is 4107 characters, which is relatively short and consistent with a meeting resolution announcement rather than a full annual report or financial report. Therefore, the appropriate classification is Board/Management Information (MANG).
2014-03-27 Chinese
独立董事2013年度述职报告（熊焰）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2013 Annual Report" and details the independent director's activities, attendance at meetings, opinions on various company matters, and efforts to protect shareholder rights during the 2013 fiscal year. It is a narrative report on the independent director's duties and opinions rather than a full company annual report or financial statement. The document length is 2259 characters, which is relatively short and focused on the independent director's report. This type of document is typically classified under Board/Management Information (MANG) as it relates to governance and management oversight rather than a full Annual Report (10-K) or Audit Report (AR).
2014-03-27 Chinese
关于向北京嘉事京西医疗器械有限公司增资扩股的可行性分析
Regulatory Filings Classification · 85% confidence The document is a detailed feasibility analysis regarding capital increase and business expansion of a subsidiary company, Beijing Jiashi Jingxi Medical Device Co., Ltd. It discusses investment plans, business scope adjustments, logistics funding needs, investor intentions, operational experience, regional business development, and financial projections. There are no indications of this being a formal financial report like an Annual Report (10-K) or Interim Report (IR). It is not an announcement of voting results, board changes, or legal proceedings. The content is a business feasibility study related to capital increase but does not constitute a formal Capital/Financing Update filing. Given the nature of the document as an internal or external business analysis report without regulatory filing characteristics, the best fitting category is Regulatory Filings (RNS) as a fallback for miscellaneous filings that do not fit other categories.
2014-03-27 Chinese
内部控制鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled '内部控制鉴证报告' which translates to 'Internal Control Assurance Report'. It references auditing standards and the evaluation of internal control effectiveness related to the financial statements as of December 31, 2013. The document is issued by a registered accounting firm and includes an assurance opinion on internal control effectiveness. It is not a full annual report (10-K), nor is it a management discussion or earnings release. It is a standalone audit-related assurance report focusing on internal control, which fits the definition of an Audit Report / Information (AR). The document length is short (1119 characters), but it contains substantive assurance content, not just an announcement or certification letter. Therefore, it should be classified as AR with high confidence. FY 2013
2014-03-27 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.